{
    "clinical_study": {
        "@rank": "83794", 
        "arm_group": [
            {
                "arm_group_label": "1 - Grape extract", 
                "arm_group_type": "Experimental", 
                "description": "Grape extract self-administered daily by mouth for 35 days during chemoradiation therapy."
            }, 
            {
                "arm_group_label": "2 - Lortab, Fentanyl patch, mouthwash", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard oral mucositis therapy such as pain medication and anti-fungal mouth washes will be prescribed according to product labels."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the ability of grape exosomes, given to the subject as grape\n      powder, as an important anti-inflammatory agent to reduce the incidence of oral mucositis\n      during radiation and chemotherapy treatment for head and neck tumors."
        }, 
        "brief_title": "Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Head and Neck Cancer", 
            "Oral Mucositis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Head and Neck Neoplasms", 
                "Stomatitis", 
                "Mucositis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to investigate the ability of plant (grape) exosomes to prevent\n      oral mucositis associated with chemoradiation treatment of head and neck cancer. Also, to be\n      evaluated is the effect of grape exosomes on the production of cytokines and immune\n      responses to tumor exosomal antigens, metabolic and molecular markers in these patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have definitive diagnosis of head and neck cancer.\n\n          -  Concurrent chemoradiation treatment of the primary tumor must be an  option for the\n             newly diagnosed cancer.\n\n          -  Patients must be informed of the investigational nature of this study and sign and\n             give written informed consent in accordance with institutional and federal\n             guidelines.\n\n          -  Absence of life limiting medical conditions\n\n          -  Ability to understand and willingness to sign a written informed consent document.\n\n          -  ECOG performance status 0, 1, or 2 (Karnofsky > 60%).\n\n          -  Patients must have adequate bone marrow function. ANC > 1000/microL and Platelet\n             count >100,000/microL\n\n          -  Age >20 years\n\n        Exclusion Criteria:\n\n          -  Known familial head and neck cancer syndrome\n\n          -  Pregnancy\n\n          -  Known HIV\n\n          -  Patients receiving immunosuppressive drugs\n\n          -  Inflammatory bowel disease\n\n          -  Active second malignancy in the last 5 years\n\n          -  Patients receiving any other investigational agent(s)\n\n          -  Patients who have received any prior chemotherapy or radiation therapy to the primary\n             head and neck cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01668849", 
            "org_study_id": "12.0220"
        }, 
        "intervention": [
            {
                "arm_group_label": "1 - Grape extract", 
                "description": "Grape extract self-administered by mouth daily for 35 days", 
                "intervention_name": "Grape extract", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "2 - Lortab, Fentanyl patch, mouthwash", 
                "description": "Lortab 5-10 mg Fentanyl patch 25 mcgs Mary's Magic Mouthwash", 
                "intervention_name": "Lortab, Fentanyl patch, mouthwash", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Lortab 5-10 mg", 
                    "Fentanyl patch 25 mcgs", 
                    "Mary's Magic Mouthwash"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fentanyl", 
                "Acetaminophen, hydrocodone drug combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Plant exosomes", 
            "Grape exosomes", 
            "Grape extract", 
            "Oral mucositis", 
            "Head and Neck Cancer", 
            "Immune response"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "link": {
            "description": "James Graham Brown Cancer Center, Louisville, Kentucky", 
            "url": "http://www.browncancercenter.org"
        }, 
        "location": {
            "contact": {
                "email": "donaldmi@ulh.org", 
                "last_name": "Donald M Miller, MD, PhD", 
                "phone": "502-562-3429"
            }, 
            "contact_backup": {
                "email": "kmcart05@louisville.edu", 
                "last_name": "Karen M Carter, BA, BSN", 
                "phone": "502-562-3429"
            }, 
            "facility": {
                "address": {
                    "city": "Louisville", 
                    "country": "United States", 
                    "state": "Kentucky", 
                    "zip": "40202"
                }, 
                "name": "James Graham Brown Cancer Center"
            }, 
            "investigator": [
                {
                    "last_name": "Donald M Miller, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jeffrey M Bumpous, MD, FACS", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Craig L Silverman, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Rebecca A Redman, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Preliminary Clinical Trial Investigating the Ability of Plant Exosomes to Abrogate Oral Mucositis Induced by Combined Chemotherapy and Radiation in Head and Neck Cancer Patients", 
        "overall_contact": {
            "email": "donaldmi@ulh.org", 
            "last_name": "Donald M Miller, MD, PhD", 
            "phone": "502-562-4370"
        }, 
        "overall_contact_backup": {
            "email": "kmcart05@louisville.edu", 
            "last_name": "Karen M Carter, BA, BSN", 
            "phone": "502-562-3690"
        }, 
        "overall_official": {
            "affiliation": "James Graham Brown Cancer Center, University of Louisville", 
            "last_name": "Donald M Miller, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Extent of pain from oral mucositis will be evaluated weekly during treatment (6 to 7 weeks) and for six months following the completion of treatment which will last approximately 30 days.", 
            "measure": "Pain caused by oral mucositis", 
            "safety_issue": "No", 
            "time_frame": "Total followup of six months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01668849"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Levels of immune biomarkers (cytokines, T cells NK Cells CD11cIL12)in the blood at the time of completion of radiation therapy will be compared to baseline levels.", 
                "measure": "Level of immune biomarkers in blood", 
                "safety_issue": "No", 
                "time_frame": "Within three days of the completion of radiation therapy which will last approximately 30 days."
            }, 
            {
                "description": "Levels of immune biomarkers (CD3, CD8, CD11b, F4/80, BRDU)in scrapings of mucosal tissue at the time of completion of radiation therapy will be compared to baseline levels.", 
                "measure": "Level of immune biomarkers in mucosal tissue", 
                "safety_issue": "No", 
                "time_frame": "Within three days of the completion of radiation therapy which will last approximately thirty days."
            }
        ], 
        "source": "James Graham Brown Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Louisville", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "James Graham Brown Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}